SignalTrace

Insulin-Use Reduction

John Montgomery3 min read

Insulin-Use Reduction

Tirzepatide’s relationship to insulin use must be understood in two distinct contexts: (1) as an alternative to insulin initiation in patients not yet on injectable therapy, and (2) as a replacement for or complement to insulin regimes in patients already using basal insulin. The clinical significance of each is different, as are the populations studied.

Context 1: Delaying or avoiding insulin initiation. In SURPASS-3 (tirzepatide vs insulin degludec once daily) and SURPASS-4 (tirzepatide vs insulin glargine), the comparator groups were initiated on basal insulin while tirzepatide patients remained on oral agents plus tirzepatide. Both trials showed tirzepatide produced greater HbA1c reduction with less hypoglycaemia than basal insulin, suggesting tirzepatide is a viable first-injectable option that avoids daily insulin injection.

Context 2: Replacing or supplementing prandial insulin in patients on basal insulin. SURPASS-6 is the most directly relevant trial for patients already on basal insulin who need further intensification. Instead of adding prandial insulin lispro three times daily (the conventional next step), patients received once-weekly tirzepatide added to their existing insulin glargine. The result: tirzepatide achieved HbA1c 6.7% vs 7.7% with insulin lispro, with hypoglycaemia events of 0.4/year vs 4.4/year. This is a 10-fold difference in hypoglycaemia burden with better glycaemic control.

The mechanism by which tirzepatide achieves this is partly glucose-dependent — both GIP and GLP-1 stimulate insulin secretion only when glucose is elevated, so the risk of hypoglycaemia is intrinsically lower than with exogenous insulin injections. Weight loss with tirzepatide (−9.0 kg in SURPASS-6) further reduces insulin resistance, which can allow basal insulin dose reduction in clinical practice, though this was not a pre-specified trial endpoint.

Ontology Insulin-Use Reduction [measured_by] SURPASS-6 Insulin-Use Reduction [measured_by] SURPASS-4 Insulin-Use Reduction [associated_with] Tirzepatide Insulin-Use Reduction [relates] Type 2 Diabetes Insulin-Use Reduction [relates] HbA1c Reduction Insulin-Use Reduction [relates] Hypoglycaemia Risk Insulin-Use Reduction [compared_against] Insulin Lispro Insulin-Use Reduction [compared_against] Insulin Glargine

Evidence Summary

SURPASS-6 — tirzepatide vs prandial insulin lispro (both on basal insulin glargine):

  • Population: 1428 adults on basal insulin, mean HbA1c 8.8%, mean age 58.8 years
  • HbA1c: −2.1% (tirzepatide) vs −1.1% (lispro); mean HbA1c at 52 wk: 6.7% vs 7.7%
  • HbA1c <7.0% achieved: 68% (tirzepatide) vs 36% (lispro)
  • Hypoglycaemia events (<54 mg/dL or severe): 0.4/year vs 4.4/year — 11× lower with tirzepatide
  • Body weight: −9.0 kg vs +3.2 kg
  • Implication: In patients inadequately controlled on basal insulin, adding tirzepatide avoids the need to add prandial insulin and gives better glucose control with far lower hypoglycaemia risk

SURPASS-4 — tirzepatide vs insulin glargine (insulin-naive, high CV risk):

  • HbA1c: −2.43%/−2.58% (10/15mg tirzepatide) vs −1.44% (glargine)
  • Hypoglycaemia: 6–9% tirzepatide vs 19% glargine (esp. lower without SU: 1–3% vs 16%)
  • Implication: Tirzepatide is a superior first-injectable choice to basal insulin in patients with CV risk, avoiding daily insulin injections entirely

Confidence: High for 52-week outcomes. Long-term data (>2 years) on insulin dose reduction, ability to discontinue basal insulin, and insulin independence are not established.

Caveats:

  • Both trials Eli Lilly-funded; no independent replication at scale
  • SURPASS-6 population on basal insulin may not generalise to patients on basal-bolus regimens requiring high daily doses
  • Weight loss partially explains insulin sensitisation effect; patients maintaining weight gain may not see same results
  • Real-world insulin dose reductions post-tirzepatide initiation are not captured in these trials

Connections

Sources

Graph View

Backlinks